# Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

> **NCT05103891** · PHASE1 · UNKNOWN · sponsor: **Pierre Fabre Medicament** · enrollment: 14 (actual)

## Conditions studied

- Melanoma
- BRAF V600 Mutation
- Unresectable Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** Binimetinib Oral Tablet

## Key facts

- **NCT ID:** NCT05103891
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-03
- **Primary completion:** 2021-11-29
- **Final completion:** 2021-11-29
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103891, "Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05103891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*